Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
T2 Biosystems Inc's Business Segments
T2 Biosystems Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Total Product Revenue
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Total Product Revenue100%
- Product Consumables70.9%
- Product Instruments22.2%
- Service6.5%
- Instrument Rentals0.5%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Total Product Revenue | $ 2 | 100% |
| Product Consumables | $ 1 | 70.9% |
| Product Instruments | $ 0 | 22.2% |
2 more segments available
Sign in to unlock the full T2 Biosystems Inc dataset.
Revenue by Product & Service Category - FY
- Product100%
- Product Consumables70.9%
- Product Instruments22.2%
- Service6.5%
- Instrument Rentals0.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 2 | 100% |
| Product Consumables | $ 1 | 70.9% |
| Product Instruments | $ 0 | 22.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full T2 Biosystems Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Total Product Revenue100%
- Product Consumables70.9%
- Product Instruments22.2%
- Service6.5%
- Instrument Rentals0.5%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Total Product Revenue | $ 2 | 100% |
| Product Consumables | $ 1 | 70.9% |
| Product Instruments | $ 0 | 22.2% |
2 more segments available
Sign in to unlock the full T2 Biosystems Inc dataset.
Description of T2 Biosystems Inc
T2 Biosystems Inc is a medical technology company that specializes in the development and commercialization of innovative diagnostic products. The company is headquartered in Lexington, Massachusetts, and was founded in 2006 by a team of scientists, engineers, and business professionals.
T2 Biosystems focuses on revolutionizing diagnostics by combining the power of magnetic resonance (MR) technology and miniaturized nanoparticles to create rapid and accurate tests for various infectious diseases, including sepsis, Lyme disease, and various other hemostasis disorders.
The flagship product of T2 Biosystems is the T2Dx Instrument, a fully automated platform that utilizes the T2 Magnetic Resonance (T2MR) technology. This technology enables the detection of pathogens, toxins, and biomarkers directly from whole blood in a matter of hours, providing faster and more precise results compared to traditional culture-based methods.
The T2Dx Instrument, along with the company's proprietary T2Candida and T2Bacteria panels, is designed to aid healthcare professionals in making informed treatment decisions rapidly. The T2Candida panel is the first FDA-cleared test for the detection of Candida infections, which are the leading cause of sepsis in ICU patients. The T2Bacteria panel, on the other hand, is the first direct-from-blood diagnostic test for bloodstream infections caused by pathogens like E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
The innovative nature of T2 Biosystems' technology lies in its ability to detect pathogens directly from clinical blood samples without the need for time-consuming blood culture procedures. This eliminates the delay associated with traditional culture-based methods, where it often takes several days to get results, enabling clinicians to administer timely and appropriate patient treatment.
T2 Biosystems has also expanded its product portfolio beyond infectious diseases. They have developed tests like the T2Hemostasis panel, which aids in the identification of hemostasis disorders like sepsis-induced coagulopathy and disseminated intravascular coagulation. Additionally, the company is actively engaged in research and development efforts to explore new applications for its T2MR technology in fields such as oncology and drug monitoring.
T2 Biosystems has received numerous accolades for its groundbreaking technologies, including FDA clearances and approvals, as well as recognition from prestigious medical and scientific organizations. The company has formed collaborations and partnerships with leading healthcare institutions and organizations worldwide to ensure widespread adoption of its innovative diagnostic solutions.
In summary, T2 Biosystems Inc is a pioneering medical technology company that leverages magnetic resonance technology and miniaturized nanoparticles to develop highly accurate and rapid diagnostic tests for infectious diseases and other medical conditions. Their innovative approach has the potential to revolutionize diagnostics and improve patient outcomes by enabling timely and targeted treatments.
T2 Biosystems focuses on revolutionizing diagnostics by combining the power of magnetic resonance (MR) technology and miniaturized nanoparticles to create rapid and accurate tests for various infectious diseases, including sepsis, Lyme disease, and various other hemostasis disorders.
The flagship product of T2 Biosystems is the T2Dx Instrument, a fully automated platform that utilizes the T2 Magnetic Resonance (T2MR) technology. This technology enables the detection of pathogens, toxins, and biomarkers directly from whole blood in a matter of hours, providing faster and more precise results compared to traditional culture-based methods.
The T2Dx Instrument, along with the company's proprietary T2Candida and T2Bacteria panels, is designed to aid healthcare professionals in making informed treatment decisions rapidly. The T2Candida panel is the first FDA-cleared test for the detection of Candida infections, which are the leading cause of sepsis in ICU patients. The T2Bacteria panel, on the other hand, is the first direct-from-blood diagnostic test for bloodstream infections caused by pathogens like E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
The innovative nature of T2 Biosystems' technology lies in its ability to detect pathogens directly from clinical blood samples without the need for time-consuming blood culture procedures. This eliminates the delay associated with traditional culture-based methods, where it often takes several days to get results, enabling clinicians to administer timely and appropriate patient treatment.
T2 Biosystems has also expanded its product portfolio beyond infectious diseases. They have developed tests like the T2Hemostasis panel, which aids in the identification of hemostasis disorders like sepsis-induced coagulopathy and disseminated intravascular coagulation. Additionally, the company is actively engaged in research and development efforts to explore new applications for its T2MR technology in fields such as oncology and drug monitoring.
T2 Biosystems has received numerous accolades for its groundbreaking technologies, including FDA clearances and approvals, as well as recognition from prestigious medical and scientific organizations. The company has formed collaborations and partnerships with leading healthcare institutions and organizations worldwide to ensure widespread adoption of its innovative diagnostic solutions.
In summary, T2 Biosystems Inc is a pioneering medical technology company that leverages magnetic resonance technology and miniaturized nanoparticles to develop highly accurate and rapid diagnostic tests for infectious diseases and other medical conditions. Their innovative approach has the potential to revolutionize diagnostics and improve patient outcomes by enabling timely and targeted treatments.
T2 Biosystems Inc. is a biotechnology company that specializes in the development and commercialization of innovative diagnostic products for medical applications, particularly in the field of infectious disease testing. The company focuses on rapid and accurate detection of pathogens, providing healthcare professionals with timely and actionable information to improve patient outcomes. Below are the extensive segments, products, and services offered by T2 Biosystems Inc.:
Segments
1. Infectious Disease Diagnostics:
- This segment focuses on developing diagnostic tools for the rapid detection of various pathogens that cause serious infections. The diagnostics aim to address critical needs in areas such as sepsis, respiratory infections, and others.
2. Sepsis Testing:
- A significant focus area for T2 Biosystems, sepsis testing involves the detection of bacteria and fungi present in the bloodstream. This enables faster diagnosis and treatment, addressing the urgency of sepsis management in clinical settings.
3. Microbial Identification:
- The company provides solutions for identifying specific microbes responsible for infections, thereby allowing for targeted and effective treatment strategies.
4. Hospital and Clinical Laboratories:
- T2 Biosystems markets its products primarily to hospitals, clinical labs, and healthcare institutions that require efficient and accurate diagnostic tools.
Products
1. T2Dx™ Instrument:
- The T2Dx instrument is a specialized diagnostic platform designed for rapid and reliable multiplex testing. It utilizes a proprietary technology that enables the simultaneous detection of multiple pathogens in a single sample, typically blood, within a few hours.
2. T2Bacteria™ Panel:
- This panel is specifically designed for the early detection of the most common bacteria that can cause sepsis. The T2Bacteria panel provides results rapidly, aiding in prompt decision-making regarding antibiotic therapy.
3. T2Fungi™ Panel:
- Similar to the T2Bacteria panel, the T2Fungi panel focuses on detecting the most prevalent fungal pathogens in the bloodstream, helping to address concerns related to invasive fungal infections.
4. T2Resistance™ Panel:
- This product goes a step further by not only identifying bacterial pathogens but also assessing their resistance to specific antibiotics. This information is critical for selecting the most effective treatment regimens.
5. Research Use Only (RUO) Products:
- T2 Biosystems also offers RUO products for laboratories engaged in research activities. These products are utilized for the development and validation of diagnostic assays in various research settings.
Services
1. Technical Support:
- T2 Biosystems provides extensive technical support to its customers, ensuring they can efficiently utilize the diagnostic platforms and interpret results accurately.
2. Training Programs:
- The company offers training programs for healthcare professionals and laboratory personnel to familiarize them with the T2Dx instrument and its panels, ensuring they can operate the devices effectively and derive maximum benefits from the technology.
3. Consultative Services:
- T2 Biosystems may also engage in consultative services, working closely with healthcare institutions to optimize the integration of their diagnostic solutions into clinical workflows.
4. Collaborative Research:
- Engaging in partnerships and collaborations with research institutions and healthcare providers, T2 Biosystems contributes to the advancement of diagnostic technologies and the improvement of infectious disease management.
Conclusion
T2 Biosystems Inc. is committed to providing cutting-edge diagnostic solutions that enhance the speed, accuracy, and efficiency of infectious disease testing. With a strong focus on addressing the complexities of sepsis and other critical infections, the company continues to innovate and expand its offerings to meet the needs of healthcare providers and improve patient outcomes.
Segments
1. Infectious Disease Diagnostics:
- This segment focuses on developing diagnostic tools for the rapid detection of various pathogens that cause serious infections. The diagnostics aim to address critical needs in areas such as sepsis, respiratory infections, and others.
2. Sepsis Testing:
- A significant focus area for T2 Biosystems, sepsis testing involves the detection of bacteria and fungi present in the bloodstream. This enables faster diagnosis and treatment, addressing the urgency of sepsis management in clinical settings.
3. Microbial Identification:
- The company provides solutions for identifying specific microbes responsible for infections, thereby allowing for targeted and effective treatment strategies.
4. Hospital and Clinical Laboratories:
- T2 Biosystems markets its products primarily to hospitals, clinical labs, and healthcare institutions that require efficient and accurate diagnostic tools.
Products
1. T2Dx™ Instrument:
- The T2Dx instrument is a specialized diagnostic platform designed for rapid and reliable multiplex testing. It utilizes a proprietary technology that enables the simultaneous detection of multiple pathogens in a single sample, typically blood, within a few hours.
2. T2Bacteria™ Panel:
- This panel is specifically designed for the early detection of the most common bacteria that can cause sepsis. The T2Bacteria panel provides results rapidly, aiding in prompt decision-making regarding antibiotic therapy.
3. T2Fungi™ Panel:
- Similar to the T2Bacteria panel, the T2Fungi panel focuses on detecting the most prevalent fungal pathogens in the bloodstream, helping to address concerns related to invasive fungal infections.
4. T2Resistance™ Panel:
- This product goes a step further by not only identifying bacterial pathogens but also assessing their resistance to specific antibiotics. This information is critical for selecting the most effective treatment regimens.
5. Research Use Only (RUO) Products:
- T2 Biosystems also offers RUO products for laboratories engaged in research activities. These products are utilized for the development and validation of diagnostic assays in various research settings.
Services
1. Technical Support:
- T2 Biosystems provides extensive technical support to its customers, ensuring they can efficiently utilize the diagnostic platforms and interpret results accurately.
2. Training Programs:
- The company offers training programs for healthcare professionals and laboratory personnel to familiarize them with the T2Dx instrument and its panels, ensuring they can operate the devices effectively and derive maximum benefits from the technology.
3. Consultative Services:
- T2 Biosystems may also engage in consultative services, working closely with healthcare institutions to optimize the integration of their diagnostic solutions into clinical workflows.
4. Collaborative Research:
- Engaging in partnerships and collaborations with research institutions and healthcare providers, T2 Biosystems contributes to the advancement of diagnostic technologies and the improvement of infectious disease management.
Conclusion
T2 Biosystems Inc. is committed to providing cutting-edge diagnostic solutions that enhance the speed, accuracy, and efficiency of infectious disease testing. With a strong focus on addressing the complexities of sepsis and other critical infections, the company continues to innovate and expand its offerings to meet the needs of healthcare providers and improve patient outcomes.